Mesothelioma Malignant

• CLINICAL_TRIALS trial_result · 2026-07-13
  Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]

  Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.

• EMA approval · 2026-06-24
  EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG

  Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision d…